|
|
|
Insider
Information: |
Baker Bros. Advisors (gp) Llc |
Relationship: |
|
City: |
New York |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
16 |
|
Direct
Shares |
608,718 |
|
Indirect Shares
|
158,658,441 |
|
|
Direct
Value |
$45,772,939 |
|
|
Indirect Value
|
$12,937,394,436 |
|
|
Total
Shares |
159,267,159 |
|
|
Total
Value |
$12,983,167,376 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
1
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
1
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
Percentage
Gain/Loss : |
0.0%
|
-76.6%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Genomic Health Inc |
GHDX |
Director, 10% Owner |
2013-07-01 |
0 |
2019-02-27 |
9,235,362 |
Premium* |
|
Acadia Pharmaceuticals Inc |
ACAD |
Director, 10% Owner |
2014-03-05 |
0 |
2016-04-01 |
41,897,946 |
Premium* |
|
Incyte Corp |
INCY |
Director, 10% Owner |
2021-05-14 |
559,963 |
2021-05-14 |
29,367,926 |
Premium* |
|
XOMA Corporation |
XOMA |
Director, 10% Owner |
2014-05-22 |
0 |
2014-05-22 |
518,849 |
Premium* |
|
Aceragen, Inc |
ACGN |
Director |
2014-07-01 |
0 |
2016-01-04 |
78,885 |
Premium* |
|
Synageva BioPharma Corp |
GEVA |
Director, 10% Owner |
2015-01-07 |
1,020 |
2015-01-07 |
11,877,394 |
Premium* |
|
Mirati Therapeutics, Inc. |
MRTX |
10% Owner |
2016-06-09 |
274 |
2016-06-09 |
30,003 |
Premium* |
|
Intellia Therapeutics, Inc. |
NTLA |
Former 10% owner |
2016-05-11 |
0 |
2016-05-11 |
976,214 |
Premium* |
|
Invitae Corp |
NVTA |
10% Owner |
2016-11-17 |
0 |
2016-11-17 |
6,554,039 |
Premium* |
|
Bellicum Pharmaceuticals, Inc |
BLCM |
10% Owner |
2017-03-24 |
0 |
2023-11-22 |
2,168,818 |
Premium* |
|
Seagen Inc |
SGEN |
Director, 10% Owner |
2023-05-31 |
46,557 |
2023-05-31 |
42,977,301 |
Premium* |
|
Neurogene |
NGNE |
Director, 10% Owner |
2023-10-05 |
904 |
2023-10-05 |
1,658,190 |
Premium* |
|
Entrada Therapeutics, Inc. |
TRDA |
10% Owner |
2022-05-16 |
0 |
2022-06-06 |
4,501,658 |
Premium* |
|
Atreca Inc |
BCEL |
Former 10% Owner |
2023-10-19 |
0 |
2023-10-19 |
2,971,128 |
Premium* |
|
Igm Biosciences, Inc. |
IGMS |
|
2023-12-13 |
0 |
2024-03-29 |
3,755,474 |
Premium* |
|
Vtv Therapeutics Inc. |
VTVT |
|
2024-03-05 |
0 |
2024-03-05 |
89,254 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
XOMA |
XOMA Corporation |
Director |
|
2014-05-22 |
4 |
A |
$0.00 |
$0 |
I/I |
25,200 |
518,849 |
0 |
- |
|
VTVT |
Vtv Therapeutics Inc. |
|
|
2024-02-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
154,971 |
|
- |
|
VTVT |
Vtv Therapeutics Inc. |
|
|
2024-03-05 |
4 |
D |
$0.00 |
$0 |
I/I |
(57,657) |
89,254 |
0 |
- |
|
GEVA |
Synageva BioPharma Corp |
Director |
|
2015-01-07 |
4 |
B |
$94.19 |
$94,190,000 |
I/I |
1,000,000 |
9,184,771 |
2.25 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2019-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
148,458 |
181,733 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2019-06-06 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,002,483) |
4,302,354 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2022-03-08 |
4 |
OE |
$20.06 |
$702,100 |
I/I |
35,000 |
42,965,004 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2022-05-13 |
4 |
A |
$0.00 |
$0 |
I/I |
3,006 |
42,966,507 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2023-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
418,350 |
232,452 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2023-05-01 |
4 |
D |
$0.00 |
$0 |
I/I |
(2,368,357) |
1,729,158 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2023-05-01 |
4 |
OE |
$36.70 |
$642,250 |
I/I |
17,500 |
42,975,257 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2023-05-02 |
4 |
GD |
$0.00 |
$0 |
D/D |
418,350 |
23,277 |
0 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2023-05-31 |
4 |
A |
$0.00 |
$0 |
I/I |
4,088 |
42,977,301 |
0 |
- |
|
NGNE |
Neurogene |
Director |
|
2019-12-20 |
4 |
B |
$8.40 |
$25,347,353 |
I/I |
3,017,542 |
12,872,664 |
2.1 |
- |
|
NGNE |
Neurogene |
Director |
|
2019-12-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(10,925,481) |
3,107,331 |
0 |
- |
|
NGNE |
Neurogene |
Director |
|
2023-08-15 |
4 |
B |
$0.63 |
$1,191,616 |
I/I |
1,888,800 |
5,246,614 |
2.25 |
- |
|
NGNE |
Neurogene |
Director |
|
2023-08-16 |
4 |
B |
$0.68 |
$156,254 |
I/I |
229,600 |
5,458,724 |
2.25 |
- |
|
NGNE |
Neurogene |
Director |
|
2023-08-17 |
4 |
B |
$0.69 |
$115,617 |
I/I |
166,942 |
5,612,949 |
2.25 |
- |
|
NGNE |
Neurogene |
Director |
|
2023-10-05 |
4 |
OE |
$0.00 |
$0 |
I/I |
592,650 |
1,658,190 |
0 |
- |
|
MRTX |
Mirati Therapeutics, Inc. |
10% Owner |
|
2015-09-16 |
4 |
B |
$45.00 |
$6,750,000 |
I/I |
150,000 |
2,744,052 |
1.5 |
- |
|
MRTX |
Mirati Therapeutics, Inc. |
10% Owner |
|
2016-03-30 |
4 |
OE |
$6.74 |
$2,112,869 |
I/I |
313,482 |
43,787 |
0 |
- |
|
MRTX |
Mirati Therapeutics, Inc. |
10% Owner |
|
2016-03-30 |
4 |
OE |
$6.74 |
$1,847 |
D/D |
274 |
137 |
0 |
- |
|
MRTX |
Mirati Therapeutics, Inc. |
10% Owner |
|
2016-06-07 |
4 |
S |
$9.44 |
$2,795,476 |
I/I |
(296,200) |
39,586 |
0 |
- |
|
MRTX |
Mirati Therapeutics, Inc. |
10% Owner |
|
2016-06-08 |
4 |
S |
$9.21 |
$1,456,480 |
I/I |
(158,100) |
37,432 |
0 |
- |
|
MRTX |
Mirati Therapeutics, Inc. |
10% Owner |
|
2016-06-09 |
4 |
S |
$9.40 |
$5,150,516 |
I/I |
(545,058) |
30,003 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|